Cosmo: A clear step forward on Vision 2030

Tuesday, January 13, 2026 @ 12:00 am

FY 2025 preliminaries showed a clear step forward on Cosmo's Vision 2030 growth ambitions, with in-line revenue driven by recurring revenues. EBITDA was at the top of the guidance range, while cash exceeded guidance. Key growth products, GI Genius and Winlevi, delivered strong performance driven by platform expansion and high patient demand.

Key catalysts include:

1. Breezula 12-month safety data (spring 2026)
2. Breezula US and EU filings (H1 2026)
3. Winlevi EU launch by partners (H1 2026)

Cosmo Flash Update

You may also be interested in

Beware of fraudulent emails impersonating the Swiss Biotech Association

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We regularly detect fraudulent emails attempting to steal your passwords — both personal and for our systems — through phishing attacks. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals
October 8, 2024

Newron: Evenamide off to a flying start - new patent & phase III trial

January 13, 2026

Pharvaris outlines 2026 strategic priorities

Topline data from CHAPTER-3, a pivotal study of deucrictibant for prophylactic treatment of HAE attacks, anticipated in 3Q2026 Preparation of NDA dossier of deucrictibant for on-demand treatment of HAE attacks ongoing; timeline remains on-track for filing in 1H2026 Recruitment ongoing in CREAATE, a pivotal study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks Est
January 12, 2026

Oculis: FDA breakthrough therapy designation for optic neuritis

Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritis Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S. Privosegtor achieved an average gain in Low Contrast Visual Acuity (LCVA) of 18 letters compared to IV steroi
January 6, 2026

Mabylon: Peanut allergy treatment in Phase I clinical trial

First study participant dosed in U.S. trial with healthy volunteers and patients with peanut allergy Novel, human-derived, half-life extended tri-specific monoclonal antibody to prevent allergic reactions MY006' tri-specific format allows for simultaneous recognition of epitopes across multiple allergens. It has been designed for sustained serum levels, high stability and continuous protection wit
December 18, 2025

Topadur: Matthias Schäfer becomes Chief Executive Officer

Founder and President of the Board Dr. Reto Naef assumes the role of Senior Scientific Advisor, continuing to support the company’s scientific direction Company enters next phase of clinical advancement with programs progressing toward strategic milestones
December 17, 2025